{Reference Type}: Case Reports
{Title}: Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: Systematic review and case.
{Author}: Snyder MH;Ampie L;DiDomenico JD;Asthagiri AR;
{Journal}: J Clin Neurosci
{Volume}: 86
{Issue}: 0
{Year}: Apr 2021
{Factor}: 2.116
{DOI}: 10.1016/j.jocn.2021.01.010
{Abstract}: Neurofibromatosis type 2 (NF2) is a rare, hereditary tumor syndrome, often requiring repeated surgeries for multiple lesions with significant cumulative morbidity. As such, non-operative management should be considered when possible for this patient population. The aim of this study is to provide a systematic review of the literature regarding this treatment strategy. A descriptive case of a patient in whom bevacizumab treatments enabled over 15 years of surgical postponement for a symptomatic spinal cord ependymoma is also provided. Evidence suggests that bevacizumab is a reasonable surgery-deferring option for cystic lesions, and it may be especially useful in NF2 patients to reduce cumulative morbidity.